Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Matthew Burke Discusses Adverse Events

      March 5, 2014
      By Matthew Burke, MBA, RN, MSN, APRN-BC
      Article

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Burke says chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body while immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent.

      Because the immune system is altered during treatment with immunotherapy agents, Burke says the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events. Also, it is difficult to predict which patients will experience severe adverse events from immunotherapy treatment.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Green and pink model of a melanoma cell

      NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma

      Ashling Wahner
      February 25th 2025
      Article

      Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.


      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      May 19th 2023
      Podcast

      Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      May 4th 2023
      Podcast

      Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Line illustration of the male genitourinary system on a yellow background

      177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL

      Jason M. Broderick
      February 13th 2025
      Article

      Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

      Related Content

      Green and pink model of a melanoma cell

      NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma

      Ashling Wahner
      February 25th 2025
      Article

      Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.


      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      May 19th 2023
      Podcast

      Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      May 4th 2023
      Podcast

      Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.


      Graphic of care providers, patients, and families conversing near large computers and health charts

      Digital Health Tool Helps Patients With Prostate Cancer During Consultations

      Bridget Hoyt
      February 14th 2025
      Article

      MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.


      Line illustration of the male genitourinary system on a yellow background

      177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL

      Jason M. Broderick
      February 13th 2025
      Article

      Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.